GLOBAL TB PROGRAMME Systematic screening for active TB – operational manual and tool to help prioritization Wolfheze 2015 Knut Lönnroth, Global TB Programme.

Slides:



Advertisements
Similar presentations
Diagnosis of Smear negative pulmonary TB in high HIV settings: RESEARCH PRIORITIES Haileyesus Getahun, Stop TB, WHO. Expert consultation on TB/HIV research.
Advertisements

TB/HIV Research Priorities: TB Preventive Therapy.
Unit 1. Introduction TB Infection Control Training for Managers at the National and Subnational Levels.
` COMPARATIVE ACCURACY OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST AND SPUTUM MICROSCOPY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN HIV POSITIVE.
USING SLFS TUBERCULOSIS SYMPTOM SCREENING TOOL FOR ADULTS A How To Guide.
Improving diagnosis TB laboratory strengthening.
Framework for improved, early case detection Knut Lönnroth DEWG meeting October 2009.
HERD Team. Using Xpert to Reach the Unreached: Mobile Diagnostics Case Finding in Nepal May 2013 – April 2015.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Living with HIV, Dying of TB Intensified TB case finding among people living with HIV Adapted from presentation by Colleen Daniels TB/HIV Advocacy Stop.
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.
GLOBAL TB PROGRAMME Systematic screening for active TB – from guideline to operational manual A TBCARE 1 (USAID) project by ATS, FHI360, KNCV, MSH, TBREACH.
Early and Improved TB case detection through the use of GeneXpert technology in Nepal.
The ninth Technical Advisory Group and National TB Managers meeting
Integrating TB into PWID Services in Indonesia The Works in Progress Dr Siti Nadia, NAP Manager; Dr Dyah Erti Mustikawati, NTP Manager Melbourne AIDS Conference.
Unit 5: Core Elements of HIV/AIDS Surveillance
Diagnosis of TB.
TB and Poverty Gillian Mann. 2 Poverty and TB Overview What do we mean by poverty and vulnerability? Higher risk of TB among the poor Lower access to.
Unit 5: IPT Isoniazid TB Preventive Therapy
National TB/ Leprosy Programme Manager
Module 10: Understanding Laboratory Data *Image courtesy of: World Lung Foundation.
Xpert in the diagnostic algorithm of pulmonary TB in adult patients who are neither high risk for HIV, nor high risk for MDR-TB Preparations for the global.
«Trust» advice bureau Target group: PLHIV PLHIV/TB Former prisoners IDUs.
Action Plan Good Health Situation of Population in Capital of Myanmar Yangon Division By DR MYA THIDA AYE.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Unit 5: Specialised Techniques: STI Prevalence Assessment and Combined STI/HIV Behavioural Surveillance Surveys #4-5-1.
Smear negative TB and HIV: urgent research priorities to inform a rolling global policy Haileyesus Getahun, MD, MPH, PhD Stop TB Department WHO/HQ.
Universal access to TB care what is the challenge, what policy, what is being implemented Cancun 3 December 2009 Léopold BLANC and TBS team TBS/STB/WHO.
NATIONAL TB 2012 INDICATOR ANALYSIS REPORT Presented by: Sandile Ginindza Lugogo Sun Hotel 05 th -7 th June 2013 Ministry of Health NTCP.
PMDT expansion is first of all expansion of DR-TB detection services Workshop on the development and implementation of supervision and patient support.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
High cost of Xpert MTB/RIF ® testing per tuberculosis case diagnosed at Partners in Hope Medical Center, a public private HIV care clinic in Lilongwe,
Recent Epidemiologic Situations of TB in Myanmar -Preliminary Review of Data from routine TB surveillance focusing on Case Finding- 9 May 2014, Nay Pyi.
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
Screening for TB among risk groups in Cambodia Dr. Mao Tan Eang, NTP Director National Center for TB and Leprosy Control, Cambodia TAG Meeting, 9-12 December.
Go to View > Master > Slide Master to edit Place, Month Year GLI and Global Fund focal point Feedback and updates Rachel Bauquerez.
Tuberculosis control in Suriname Situational analysis.
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia & Dr. Michael Lynch Epidemiologist.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia.
Screening of risk groups Facilitator: Eugene McCray Raporteur: Paula Samo Gudo.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
Early TB case detection in pre-trial detention centers (SIZOs) and prison colonies in Ukraine 46 th Union World Conference on Lung Health Cape Town, South.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.
Early DETECTion and integrated management of TuBerculosis in europe: E-DETECT TB Professor Ibrahim Abubakar Director, Institute for Global Health University.
Roundtable. Detection and treatment of TB Andrew Black.
Gap Analysis: Tuberculosis Care in Malawi Round 11 proposal to the Global Fund to Fight AIDS, Tuberculosis and Malaria Africa 3: Team Malawi Arianna, Babatunde,
Rauni Ruohonen FILHA Priorities of TB control in penitentiary care.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
TB: Can we end it as AIDS in the future? Presentation for discussion RIHES December 9, 2015.
Strengthening TB and HIV&AIDS Responses in East Central Uganda Strengthening Laboratory TB diagnostic capacity of peripheral laboratories in East Central.
CAMBODIA Application to the Global Fund New Funding Model Tom Hiatt Global TBTEAM meeting June 2014.
New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.
TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA
Monitoring and Evaluation Frameworks
Addressing the challenges and successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya Masini E & Olwande C National.
Authors: Chepchieng DB1, Munyua MM2, Ngatia R2
Dr. Kathure, Weyenga and Langat
Find and Treat All Missing Persons with TB
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Introduction Acknowledgments Identified need Project objective
DOTS IMPACT TO TUBERCULOSIS IN LITHUANIA
WP 4: Outreach for early diagnosis
5th edition NTP MANUAL OF PROCEDURES Case Finding
TB Screening and Differentiated Service Delivery: State of the Art
Presentation transcript:

GLOBAL TB PROGRAMME Systematic screening for active TB – operational manual and tool to help prioritization Wolfheze 2015 Knut Lönnroth, Global TB Programme WHO 1

GLOBAL TB PROGRAMME Strong recommendations = Should be screened in all settings 1.Household contacts and other close contacts should be systematically screened for active TB. 2.People living with HIV should be systematically screened for active TB at each visit to a health facility. 3.Systematic screening for active TB should be done in current and former workers in workplaces with silica exposure 2

GLOBAL TB PROGRAMME Conditional recommendations = prioritization needed 4.Systematic screening for active TB should be considered in prisons and other penitentiary institutions. (including staff) 5.Systematic screening for active TB should be considered in people with untreated fibrotic CXR lesion. 6.In settings where the TB prevalence is ≥100/100,000 in the general population, systematic screening for active TB should be considered among people who are seeking care or who are in care and belong to selected risk groups (see remarks, including staff) 3

GLOBAL TB PROGRAMME Conditional recommendations, cont. 7.A. Systematic screening may be considered for geographically defined sub-populations with extremely high levels of undetected TB (>1% prevalence) B. Systematic screening may be considered also for other sub- populations with very poor health care access, such as urban slum dwellers, homeless people, people living remote areas with poor access, indigenous populations, migrants, and other vulnerable groups. 4

GLOBAL TB PROGRAMME Operational guide

GLOBAL TB PROGRAMME Planning & implementation cycle 1. Situation assessment / 6. Monitoring and evaluation 2. (Re-)Define goals and specific objectives 3. (Re-) prioritization of risk-groups 4. Choose screening and diagnostic algorithms 5. Planning, budgeting, implementation

GLOBAL TB PROGRAMME Tool for prioritization of risk groups (slides from Cecily Miller, UCSF)  Estimates the following for each risk group and each algorithm:  Case-finding yield (true and false positive)  Number needed to screen to detect one true case  Total cost  Cost per true case detected  Allows for comparison of estimates  Across risk groups  Across screening algorithms

GLOBAL TB PROGRAMME Step 1– Select the country  User begins by selecting the country for exploration:  Country selection auto-populates data on:  Total population size  TB prevalence per 100,000  HIV prevalence  Household size (when available) Cambodia

GLOBAL TB PROGRAMME Step 2 – Select risk groups PLHIV Contacts Miners Diabetics

GLOBAL TB PROGRAMME Step 3 – Estimating risk group size 2 ways to specify population size of each risk group: 1.Estimate size of risk group as % of country population (default) 2.Estimate absolute size of risk group PLHIV Contacts Miners Diabetics

GLOBAL TB PROGRAMME Step 4 – Estimating TB prevalence in each risk group 2 ways to specify TB prevalence within risk groups: 1.Enter or estimate relative risk of TB in risk group compared to general population (default) 2.Enter or estimate absolute TB prevalence per 100k PLHIV Contacts Miners Diabetics

GLOBAL TB PROGRAMME Step 5 – Reachability & acceptability Contacts PLHIV Miners Diabetics  Enter the % of the risk group expected to be reachable  Enter the % of the risk group expected to accept screening  Findings from acceptability systematic review pre-filled as suggested values

GLOBAL TB PROGRAMME Algorithms (default, with changeable values for sensitivity and specificity) 1a. Cough screen  Sputum smear microscopy 1b. Cough screen  Xpert 1c. Cough screen  CXR  Sputum smear microscopy 1d. Cough screen  CXR  Xpert 2a. Any symptom screen  Sputum smear microscopy 2b. Any symptom screen  Xpert 2c. Any symptom screen  CXR  Sputum smear microscopy 2d. Any symptom screen  CXR  Xpert 3a. CXR  Sputum smear microscopy 3b.CXR  Xpert Note: - Clinical diagnosis / empirical treatment not considered for persons negative on diagnostic test in current version - Culture can be included, by replacing Xpert assumptions

GLOBAL TB PROGRAMME Step 6 – costs  User estimates cost of per person screened: 1.Test cost 2.Operational cost

GLOBAL TB PROGRAMME

GLOBAL TB PROGRAMME Total potential yield

GLOBAL TB PROGRAMME

GLOBAL TB PROGRAMME No. of true and false positive cases Cough  smear microscopy Cough  CXR  Xpert CXR  Xpert Algorithm CXR  Xpert Cough  CXR  Xpert Cough  smear microscopy

GLOBAL TB PROGRAMME Costs per true case, across algorithms:

GLOBAL TB PROGRAMME Incremental cost-effectiveness

GLOBAL TB PROGRAMME Tool considerations & limitations  Focus on pulmonary TB (bacteriologically confirmable)  The tool is exploratory, not for detailed planning purposes  Tool estimates are based on several assumptions  The uncertainty of each estimate compounds the uncertainty of the overall estimates  Does not model the impact on transmission and TB incidence  Does not estimate patient cost (only provider)  Algorithm options developed mostly for low- and middle- income countries

GLOBAL TB PROGRAMME Thank you Acknowledgements Cecily Miller Nobu Nishikiori Anja van't Hoog Screening operational guide review committee Send feedback to &